CN / EN

Huayi Pharmaceuticals (Anhui) Co., Ltd. is the first company passing European certification in Anhui. As a contract development and manufacturing organization (CDMO) dedicated to providing various dosage forms for Chinese and European markets, the company has been granted with EU GMP certificate in August 2010 after passing the GMP inspection by Medicines and Healthcare Products Regulatory Agency (MHRA). The certificate has been updated three times after re-inspections by MHRA. The company also has passed the quality inspections by more than 200 companies at home and abroad including Teva, KrKa and Novartis etc. and has passed several GMP compliance inspections by Chinese authorities (NMPA).


Since its establishment, the company has been providing joint venture cooperation, multiple dosage forms pharmaceutical development, commercial production on a contract basis, chemical synthesis research, and drug clinical testing services for research institutions and pharmaceutical sales enterprises etc. at home and abroad and has gradually built an open CDMO platform for international markets, which is dedicated in R&D of multiple dosage forms and focused on manufacturing of oral preparations, providing chemical synthesis as supplementary service.

Adhering to the corporate value of “create value and benefit for the world” and corporate spirit of “keep pragmatic and innovative all the time”, Huayi is fully engaged in providing customers with pharmaceutical development and production services of high efficiency, high quality and controllable cost and making high quality drugs at affordable cost. Huayi sincerely looks forward to cooperating with partners from all over the world on the pharmaceutical development, contract manufacture, MA application in both China and Europe and joint venture cooperation and developing both the international and domestic markets.


  • 2.5 billion

    tablets/capsules manufactured per year on a contract basis


  • 100 ?

    products successfully developed and commercialized


  • 200 ?

    quality audits from well-known pharmaceutical companies at home and abroad


Milestone

  • 2024

    ? Synthesis laboratory under construction

    Highly potent solid preparation workshop under construction

  • 2023

    The Fourth Council Member Unit of the All-China Federation of Industry and Commerce Association of Pharmaceutical Commerce

    Top 20 Chinese Pharmaceutical CDMO Enterprises in 2023

    Main Structure Construction for Phase I Preparation Building in the New Site (Shenyang Road Site) completed

    Construction of synthesis laboratory started

    Construction of highly potent solid preparation workshop started

    Exports to EU reached 2.5 billion tablets

    First domestic product commercialized

  • 2022

    On September 13, 2022, the company was elected as the Chairman Unit of Anhui Preparation CDMO Industry Alliance

    Top 20 Chinese Pharmaceutical CDMO Enterprises in 2022

    2022 (Industry) Leading Enterprise

  • 2021

    On October 8, 2021, Huayi’s Technical Center was established.

    In June 2021, the company passed the remote re-inspection by MHRA.


  • 2020

    On July 14th, 2020, the first bottle of liquid preparation was produced.

  • 2019

    In 2019, the company started the construction of oral liquid preparation and high potency workshop


  • 2018

    In 2018, the contract manufacture output reached 1.6 billion units


  • 2016

    ? In 2016, the company passed the on-site re-inspection by MHRA without any major deficiency

    ? The workshop extension has passed MHRA certification and the company's annual capacity was increased to 3 billion units


  • 2012

    In 2012, the company passed the on-site re-inspection by MHRA.


  • 2010

    In 2010, the company passed the on-site inspection by MHRA and started to perform the contract development, technical transfer and contract manufacture for EU market.


  • 2006

    In 2006, Huayi Pharmaceuticals (Anhui) Co., Ltd. was established and the workshop construction started.